Accession Number: | 0000899866-21-000070 |
Date: | 2021-07-21 |
Issuer: | ALEXION PHARMACEUTICALS, INC. (ALXN) |
Original Submission Date: |
BRENNAN DAVID R
C/O ALEXION PHARMACEUTICALS, INC
121 SEAPORT BOULEVARD
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK, PAR VALUE $.0001 PER SHARE | 2021-07-21 | D | 20,873 | d | $0.00 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
OPTION TO PURCHASE COMMON STOCK | 155.01 | 2021-07-21 | deemed execution date | D | 2,343 (d) | 2016-05-06 | 2025-05-06 | common stock, par value $.0001 per share 2,343 | $155.01 | 0 | direct | |
OPTION TO PURCHASE COMMON STOCK | 167.97 | 2021-07-21 | deemed execution date | D | 2,706 (d) | 2015-07-22 | 2024-07-22 | common stock, par value $.0001 per share 2,706 | $167.97 | 0 | direct | |
OPTION TO PURCHASE COMMON STOCK | 138.86 | 2021-07-21 | deemed execution date | D | 2,294 (d) | 2017-05-11 | 2026-05-11 | common stock, par value $.0001 per share 2,294 | $138.86 | 0 | direct |
ID | footnote |
---|---|
f1 | represents shares of alexion common stock disposed in connection with the agreement and plan of merger (the "merger agreement") dated as of december 12, 2020, by and among alexion and astrazeneca plc. in accordance with the merger agreement, upon the first effective time (as defined in the merger agreement), each share of alexion common stock was converted into the right to receive (i) 2.1423 american depositary shares (adss) of astrazeneca plc and (ii) $60.00 in cash (the "merger consideration"). upon the first effective time, 3,336 restricted stock units were fully vested and cancelled and converted into the right to receive the merger consideration with respect to each share of alexion common stock subject to such restricted stock units. |
f2 | upon the first effective time, these options were cancelled and converted into the right to receive the product obtained by multiplying (a) the excess, if any, of the value of the merger consideration over the exercise price per share of the alexion common stock subject to such options immediately prior to the first effective time by (b) the number of shares of alexion common stock subject to such option immediately prior to the first effective time by (ii) the value of the merger consideration. |